Vireta lists on Cyprus Stock Exchange
September 13, 2013 8:45 am

The Cyprus Stock Exchange (CSE) announced that it has accepted the listing on its Emerging Companies Market of 100 shares of nominal value €260 of “Vireta Investments Plc” with a listing price of €260.

Eurivex, a Cyprus Investment Firm, regulated by CySEC is the company’s Nominated Advisor and guided the company to its successful listing.

The objective of Vireta is to create value from the acquisition of companies in retail trade and distribution sectors based in Eastern Europe. The trading of the above securities will commence on September 16, 2013 and the Cyprus Stock Exchange will undertake the maintenance of the above Registry in the Central Depository/Registry of the CSE.

The Greek and English code of the shares is ΒΙΡΕ/ VIRE respectively, while the ISIN Code will be CY0103680217.

Company

  • 18 Kyriacou Matsi Ave.

  • Victory Tower, 1 st floor

  • Nicosia 1082, Cyprus

Subscribe to our latest news

Disclaimer & Regulatory information
Eurivex Ltd is a Cyprus Investment Firm, authorized and regulated by the Cyprus Securities and Exchange Commission (CySEC), License number 114/10.
Company Reg. HE 255430. Headquartered and based in Cyprus, member of EU.

Risk warning: Investing in financial instruments and other derivatives involves a high degree of risk and may not be suitable to all investors. Trading in such financial instruments can result in both an increase and decrease in capital. If you invest through Eurivex Ltd, the value of investments may go down and your capital will be at risk. Eurivex Ltd operates a secondary market but there is no guarantee that all buy/sell orders will be completed at the desired prices and there is a risk that an order may not be completed in the Eurivex secondary market if there is no matching order. There is no guarantee that you will be able to exit early by selling your investment. Eurivex Ltd does not provide investment, tax or legal advice. If you are unsure about the suitability of an investment, you should speak to a financial adviser. Please refer to our Risk Warning available on our web site for further information.